Join Growin Stock Community!

Gt biopharma, inc.GTBP.US Overview

US StockHealthcare
(No presentation for GTBP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GTBP AI Insights

GTBP Overall Performance

GTBP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GTBP Recent Performance

-3.06%

Gt biopharma, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

GTBP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GTBP Key Information

GTBP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GTBP Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Price of GTBP

GTBP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GTBP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.17
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.17
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GTBP's latest earnings report released?

    The most recent financial report for Gt biopharma, inc. (GTBP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GTBP's short-term business performance and financial health. For the latest updates on GTBP's earnings releases, visit this page regularly.

  • How much cash does GTBP have?

    At the end of the period, Gt biopharma, inc. (GTBP) held Total Cash and Cash Equivalents of 2.62M, accounting for 0.61 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GTBP's EPS continuing to grow?

    According to the past four quarterly reports, Gt biopharma, inc. (GTBP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.83. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GTBP?

    Gt biopharma, inc. (GTBP)'s Free Cash Flow (FCF) for the period is -3.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 34.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.